HBV Vaccines: Advances and Development

Area of Science:

• Hepatology
• Immunology
• Vaccinology

Background:

• Hepatitis B virus (HBV) infection is a major cause of liver cirrhosis and hepatocellular carcinoma (HCC).
• Universal HBV vaccination programs have successfully decreased the prevalence of HBV infection and related liver diseases.
• Early vaccines were derived from plasma, while current ones utilize recombinant DNA technology.

Purpose of the Study:

• To review existing Hepatitis B virus (HBV) vaccines and discuss recent advancements in developing novel vaccines.
• To highlight the importance of prophylactic vaccination in preventing HBV infection through neutralizing antibodies.
• To explore the need for therapeutic vaccines that induce T cell responses against multiple HBV antigens.

Main Methods:

• Review of existing literature on HBV vaccines.
• Analysis of the evolution of HBV vaccine development from plasma-derived to recombinant technologies.
• Discussion of the immunological mechanisms targeted by prophylactic and therapeutic vaccines.

Main Results:

• HBV vaccination has drastically reduced HBV infection, liver cirrhosis, and HCC globally.
• Current vaccines are effective and safe but face challenges from HBV variants and immunosuppression.
• Prophylactic vaccines induce antibodies, while therapeutic vaccines require broader T cell responses.

Conclusions:

• Despite the success of current HBV vaccines, continuous research is vital for enhanced efficacy, duration, and accessibility.
• New vaccine strategies are needed to combat HBV variants and virus-induced immunosuppression.
• Developing effective therapeutic vaccines remains a critical goal for HBV eradication.